Our commitment to excellence started with the construction of a purpose-built facility equipped with the latest technology and infrastructure. This laid the foundation for a center of excellence that would become synonymous with groundbreaking advancements in life sciences.

In 2020, Dow Institute of Life Sciences achieved a significant milestone by obtaining a Manufacturing License from the Drug Regulatory Authority of Pakistan (DRAP). This endorsement marked our dedication to upholding the highest standards in pharmaceutical manufacturing. Additionally, the approval of the Sera Section showcased our expertise in the production of essential biological products.

Building on our success, the year 2021 saw Dow Institute of Life Sciences attaining approval for its Vaccine Section. This pivotal moment allowed us to contribute to global health by developing and producing vaccines that address critical healthcare needs. Our commitment to research, development, and manufacturing positions us as a key player in the fight against infectious diseases.